The results indicate that Aβ42, T-tau and P-tau181 in blood neurogenic exosomes can be effectively used as biomarkers for AD, which can be applied in the diagnosis, screening, prognosis prediction and disease monitoring of AD. Here, MAPT is linked to Alzheimer disease.